Meeting Chairs
- Franz Schaefer, aHUS Registry Scientific Advisory Board Chair
- Gema Ariceta, aHUS Registry Scientific Advisory Board Co-Chair
Meeting Rationale
The Global aHUS Registry Investigators’ Meeting explored the transition to the Ravulizumab in aHUS Registry, highlighting the scientific value of real-world evidence, recent registry achievements, protocol updates, and future evidence generation opportunities.Watch the recording to hear expert perspectives and learn how continued investigator engagement will help advance the understanding of aHUS and ravulizumab in clinical practice.
Key Discussion Topics
- Transition from the aHUS disease registry to the new Ravulizumab in aHUS Registry.
- Scientific value of real-world evidence and recent registry publications.
- Protocol amendment updates, patient eligibility, follow-up requirements, and operational considerations.
- Future evidence generation opportunities and the importance of ongoing investigator engagement and patient recruitment.
Duration: 120 minutes (recorded session)
Franz Schaefer, MD, PhD
Head, Section for Pediatric Nephrology
Heidelberg University Hospital, Germany
Gema Ariceta Iraola, MD, MS, PhD
Head, Pediatric Nephrology Services
Vall d'Hebron University Hospital, Spain
Vall d'Hebron University Hospital, Spain
